Roflumilast

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Asthma

Conditions

Asthma

Trial Timeline

Dec 1, 2003 → Jun 1, 2005

NCT ID

NCT00076076

About Roflumilast

Roflumilast is a phase 3 stage product being developed by AstraZeneca for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT00076076. Target conditions include Asthma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03381573	Pre-clinical	Completed	Dec 15, 2013	Sep 16, 2022	COPD
NCT02068456	Pre-clinical	Completed	Sep 18, 2012	Apr 26, 2017	Chronic Obstructive Pulmonary Disease
NCT01354782	Phase 1	Completed	May 1, 2011	Sep 1, 2011	Chronic Obstructive Pulmonary Disease
NCT01140542	Phase 2	Completed	Aug 1, 2006	Mar 1, 2008	Diabetes Mellitus Type 2
NCT00246935	Phase 3	Completed	May 1, 2005	Oct 1, 2007	Chronic Obstructive Pulmonary Disease (COPD)
NCT00246922	Phase 3	Completed	Dec 1, 2004	Oct 1, 2007	Bronchial Asthma
NCT00242294	Phase 2/3	Completed	Nov 1, 2004	Mar 1, 2007	Chronic Obstructive Pulmonary Disease (COPD)
NCT00108823	Phase 3	Completed	Oct 1, 2004	—	Chronic Obstructive Pulmonary Disease, COPD
NCT00242307	Phase 2/3	Completed	May 1, 2004	Jun 1, 2007	Bronchial Asthma
NCT00163475	Phase 3	Completed	May 1, 2004	Aug 1, 2005	Asthma
NCT00076076	Phase 3	Completed	Dec 1, 2003	Jun 1, 2005	Asthma
NCT00076089	Phase 3	Completed	Dec 1, 2003	Dec 1, 2005	Chronic Obstructive Pulmonary Disease
NCT00073177	Phase 3	Completed	Nov 1, 2003	—	Asthma
NCT00062582	Phase 3	Completed	Jun 1, 2003	—	Chronic Obstructive Pulmonary Disease
NCT00163527	Phase 3	Completed	Apr 1, 2003	Nov 1, 2005	Asthma
NCT00430729	Phase 3	Completed	Jan 1, 2003	—	Chronic Obstructive Pulmonary Disease

Competing Products

20 competing products in Asthma

See all competitors

Product	Company	Stage	Hype Score
Roflumilast	AstraZeneca	Phase 3	77
Dulera	Merck	Approved	85
Briquilimab	Jasper Therapeutics	Phase 1	25
YHD001 dose level 1 + YHD001 dose level 2 + Singulair + Placebo	Yuhan	Phase 2	52
Omalizumab	Daiichi Sankyo	Phase 3	77
Omalizumab	Daiichi Sankyo	Phase 3	77
Tacrolimus Inhalation Aerosol	Astellas Pharma	Phase 2	52
Regadenoson + Placebo	Astellas Pharma	Approved	85
Tacrolimus	Astellas Pharma	Phase 2	52
tacrolimus	Astellas Pharma	Phase 2	52
Zero-dose + 90 mcg of PROAIR® HFA + 180 mcg of 90 mcg of PROAIR® HFA + 90 mcg of albuterol sulfate inhalation aerosol	Sun Pharmaceutical	Phase 3	77
rabeprazole	Eisai	Phase 3	77
KHK4563 + KHK4563 + KHK4563 + Placebo	Kyowa Kirin	Phase 2	52
Placebo + Brodalumab	Kyowa Kirin	Phase 2	52
ONO-6950 + ONO-6950 + Montelukast + Placebo	Ono Pharmaceutical	Phase 2	52
ONO-6950 + Placebo + Montelukast	Ono Pharmaceutical	Phase 2	52
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + Placebo	Cipla	Phase 3	77
Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo	Cipla	Phase 3	77
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + Placebo	Cipla	Phase 3	77
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT	Cipla	Phase 3	77

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved